tbuckley/cabot-search huggingface dataset:
Hypertensive disorder of pregnancy
Authors: Robert Charles, Christopher Swales, Tess Bonnett, Phil Bonnett
Journal: BMJ (2017)

A 41 year old woman (gravida 1 para 0) presented to the antenatal day unit at 32 weeks’ gestation with a blood pressure of 157/93 mm Hg. Her first recorded BMI in pregnancy was 32. She was a non-smoker and had no known drug allergies. Her history included a thoracic spine fracture and two lumbar disc protrusions that had been asymptomatic since 2002. Earlier in the day, she had a headache that was relieved by paracetamol. Urinalysis showed 1+protein and a urinary protein creatinine ratio of 19 mg/mmol. Further measurements found a blood pressure of 163/96 mm Hg. The patient was admitted to the antenatal ward and started on an antihypertensive. Once her blood pressure was stable she was discharged with regular follow-up.

At 34 weeks’ gestation she presented to labour ward triage with a blood pressure of 158/98 m Hg despite antihypertensive treatment. She was admitted to the antenatal ward, her antihypertensive therapy was increased, and a second line agent was started. Urinary protein creatinine ratio was 39 mg/mmol; 24 hour urine collection showed 540 mg/24 hour of protein. An ultrasound scan for growth, liquor volume, and umbilical cord dopplers was normal. Induction of labour was arranged at 37 weeks’ gestation.



### 1. What is the most likely diagnosis and what are the risk factors in this case?

#### Short answer

Gestational hypertension developing into pre-eclampsia. Risk factors include nulliparity, maternal age >40 years, and body mass index >25.

#### Discussion

Hypertension can be graded according to severity (box 1).1 The National Institute for Health and Care Excellence (NICE) classifies hypertensive disorder of pregnancy as chronic hypertension, gestational hypertension, or pre-eclampsia.1 Chronic hypertension is defined as pre-existing hypertension or hypertension diagnosed before 20 weeks’ gestation. Gestational hypertension is new …
CBIO-38CHARACTERISTICS OF microRNA EXPRESSIONS IN GLIOBLASTOMA WITH LEPTOMENINGEAL DISSEMINATION OR METASTASIS
Authors: Takashi Sasayama, Mitsutoshi Nakada, Kazuhiro Tanaka, Naoya Hashimoto, Manabu Kinoshita, Naoki Kagawa, Katsu Mizukawa, Hirotomo Tanaka, Takashi Mizowaki, Hiroaki Nagashima, Junichi Sakata, Eiji Kohmura
Journal: Neuro-Oncology (2015)

BACKGROUND: Recurrent glioblastomas (GBMs) occasionally appear as disseminated or metastatic lesions at sites distant from the primary tumor, and clinical course of these GBMs is miserable. MicroRNAs (miRs) are small, noncoding RNAs, which regulate gene expression and various biological cellular events. The aim of this study is to clarify the miRs which promote dissemination or metastasis in GBMs. METHODS: Twenty-two supratentorial GBMs with leptomeningeal dissemination or metastasis to spinal cord or medulla oblongata (GBM with D/M) and 53 GBMs without D/M were analyzed. The expression levels of twenty-two miRs, which were known to be related to GBM, were examined using TaqMan real-time RT-PCR. After then, several miRs which were significantly upregulated or downregulated in GBMs with D/M were biologically examined by WST assay and migration assay, etc. RESULTS: Eight miRs (miR-7, -29b, -34a, -101, -124, -128a, -137, -218) were statistically decreased in GBM with D/M as compared with that without D/M. On the other hand, no miR was statistically increased in GBM with D/M. We focused on three miRs (miR-29b, miR-34a, and miR-101) that were most significantly decreased in GBM with D/M. Applying the mimic RNA for these miRs inhibited cell proliferation in WST assay and inhibited migration in migration assay in U87 and A172 glioma cells. In contrast, inhibitor of these miRs promoted cell migration in glioma cells. CONCLUSION: Expressions of several miRs (miR-29b, miR-34a, and miR-101) are characteristics in GBM with D/M. These miRs may be a predictive marker of dissemination or metastasis in GBMs.
Anti-Inflammatory Effects of Moxifloxacin with and without Anti Toll-Like Receptors and Protein-Tyrosine-Kinase Inhibitors in Human Monocytes Stimulated with Aspergillus fumigatus.
Authors: Ina Fabian, Avital Levitov, Debby Haite, Drora Halperin, Jacob Romano, Nir Osherov, Itamar Shalit
Journal: Blood (2004)
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
Authors: Steven J. Skates, Mark H. Greene, Saundra S. Buys, Phuong L. Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, John O. Schorge, Mark Sherman, Mary B. Daly, Thomas Rutherford, Wendy R. Brewster, David M. O'Malley, Edward Partridge, John Boggess, Charles W. Drescher, Claudine Isaacs, Andrew Berchuck, Susan Domchek, Susan A. Davidson, Robert Edwards, Steven A. Elg, Katie Wakeley, Kelly-Anne Phillips, Deborah Armstrong, Ira Horowitz, Carol J. Fabian, Joan Walker, Patrick M. Sluss, William Welch, Lori Minasian, Nora K. Horick, Carol H. Kasten, Susan Nayfield, David Alberts, Dianne M. Finkelstein, Karen H. Lu
Journal: Clinical Cancer Research (2017)

Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6- to 12-monthly CA125 > 35 U/mL.Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject's baseline, which triggered transvaginal ultrasound. Specificity and positive predictive value (PPV) were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls.Results: Specificity for ultrasound referral was 92% versus 90% (P = 0.0001), and PPV was 4.6% versus 10% (P > 0.10). Eighteen of 19 malignant ovarian neoplasms [prevalent = 4, incident = 6, risk-reducing salpingo-oophorectomy (RRSO) = 9] were detected via screening or RRSO. Among incident cases (which best reflect long-term screening performance), three of six invasive cancers were early-stage (I/II; 50% vs. 10% historical BRCA1 controls; P = 0.016). Six of nine RRSO-related cases were stage I. ROCA flagged three of six (50%) incident cases before CA125 exceeded 35 U/mL. Eight of nine patients with stages 0/I/II ovarian cancer were alive at last follow-up (median 6 years).Conclusions: For screened women at familial/genetic ovarian cancer risk, ROCA q3 months had better early-stage sensitivity at high specificity, and low yet possibly acceptable PPV compared with CA125 > 35 U/mL q6/q12 months, warranting further larger cohort evaluation. Clin Cancer Res; 23(14); 3628-37. ©2017 AACR.
E-Selectin Inhibitor GMI-1271 Works in Combination with Low-Molecular Weight Heparin to Decrease Venous Thrombosis and Bleeding Risk in a Mouse Model
Authors: Daniel Durant Myers, Shirely K. Wrobleski, Krus Kelsey, Diana Farris, Diaz A. Jose, Henke K. Peter, Suman L. Sood, Thomas W. Wakefield, John L. Magnani
Journal: Blood (2014)
Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction.
Authors: Iris Isufi, Amy Barile, Kerry Russell, Kasia Hryniewicz, Julie Baker, Erin Medoff, Daniel Jacoby, Forrester Lee, Francine M Foss, Dennis L. Cooper, Stuart Seropian
Journal: Blood (2010)
Hodgkin’s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.
Authors: Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Stefano Monti, Wen Chen, Paola Dal Cin, Jeremy S. Abramson, Kunihiko Takeyama, Todd R. Golub, Jon C. Aster, Gabriel A. Rabinovich, Margaret A. Shipp
Journal: Blood (2006)
Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients
Authors: Inger S. Nijhof, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, Paul W. H. I. Parren, Henk Lokhorst, Tuna Mutis
Journal: Blood (2012)
Machine-Made Man
Authors: Geoffrey Rubin
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Ubiquitin E3 Ligase, Tripartite Motif Protein 68 (TRIM68) Inhibits TCP-1 b Function by Proteasome-Mediated Degradation and May Overcome Imatinib-Resistance.
Authors: Yasuhito Terui, Ryoko Kuniyoshi, Yuji Mishima, Yuko Mishima, Kiyohiko Hatake
Journal: Blood (2009)
Single-Agent Vincristine Sulfate Liposomes Injection (Marqibo®) Compared to Historical Single-Agent Therapy for Adults with Advanced, Relapsed and/or Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
Authors: Olivia R. Deitcher, Susan O'Brien, Steven R. Deitcher, Deborah A. Thomas, Hagop M. Kantarjian
Journal: Blood (2011)
Circulating Human Fetal Mesenchymal Stem Cells Support Ltc-Ic and Express a Cytokine Profile To Maintain Quiescence of Co-Circulating Hemopoietic Stem Cells Circulating Human Fetal Mesenchymal Stem Cells Support LTC-IC and Express a Cytokine Profile To Maintain Quiescence of Co-Circulating Hemopoietic Stem Cells.
Authors: Josu de la Fuente, Jerry Chan, Keelin O’Donoghue, Jaspal Kaeda, Sailesh Kumar, Nicholas M. Fisk, Irene A.G. Roberts
Journal: Blood (2004)
ATPS-76ESTROGEN RECEPTOR β AGONISTS: NOVEL THERAPEUTIC AGENTS FOR GLIOBLASTOMA
Authors: Gangadhara Reddy Sareddy, David Cavazos, Aleksandra Gruslova, Andrew Brenner, Ratna Vadlamudi
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) are the most common primary brain tumors with poor prognosis. A gender bias exists in the development of GBM with greater incidence of GBM in males compared to females, suggesting the tumor suppressive role of estrogen. However, estrogen as potential therapy for GBM is limited due to safety concerns. Therefore, alternative agents that mimic estrogen effects are needed. Estrogen effects are mediated though Estrogen Receptor α (ERα) and Estrogen Receptor β (ERβ). ERβ functions as a tissue-specific tumor suppressor. Our studies demonstrated that GBM uniquely express ERβ but not ERα. Recent studies identified Liquiritigenin and LY500307 as selective ERβ agonists that are currently in clinical trials for treating hot flashes and Schizophrenia. The objective of this study is to determine the therapeutic effects of novel ERβ agonists and to determine their mechanism(s) of action. Treatment with ERβ agonists significantly reduced the proliferation of GBM cells with no activity on normal astrocytes. Overexpression of ERβ reduced proliferation of GBM cells and knockdown of ERβ compromised the effect of ERβ agonists. ERβ agonists mediated apoptosis of GBM involve genes activated by both ERβ- classical as well as non-classical pathways and also involve p38MAPK and JNK pathways. Since Glioma Stem Cells (GSCs) are implicated in tumor initiation, invasion and therapy resistance, we also tested the effect of ERβ agonists on GSCs. ERβ agonists significantly inhibited the neurosphere formation and self-renewal of GSCs and also reduced the stemness and induced differentiation and apoptosis. RNA sequencing analysis revealed several novel pathways related to apoptosis, cell cycle, stem cells and differentiation were significantly modulated by ERβ agonists. Further, Liquiritigenin and LY500307 treatment significantly reduced the in vivo tumor growth and promoted apoptosis of tumors. Together, our results demonstrate that ERβ agonists as a potential therapeutic agents for treatment of GBM.
Transplantation of Peripheral Blood Stem Cells from Unrelated Donors Is Not Associated with Inferior Survival Compared to Bone Marrow Transplantation in Children with Hematologic Malignancies - A Registry Analysis from the German/Austrian Pediatric Registry for Stem Cell Transplantation (PRST).
Authors: Roland Meisel, Caroline Spohr, Thomas Klingebiel, Dagmar Dilloo
Journal: Blood (2006)
Compound Heterozygosity for a Novel Mutation Combined with G Insertion in Exon 13 Causes Severe Factor XI Deficiency in Patients of Japanese Origin.
Authors: Nobutsune Ishikawa, Shinichiro Yasunaga, Motoaki Ohtsubo, Yoshihiro Takihara, Takashi Sato, Masao Kobayashi
Journal: Blood (2005)
Significant and Morbid Changes in Heart Rate Variability Precedes and Complicates Symptomatic Hypotension in Peripheral Blood Stem Cell Apheresis.
Authors: Hirohisa Nakamae, Yoshiki Terada, Mika Akahori, Takahiko Nakane, Kiyoyuki Hagihara, Yasunobu Takeoka, Taro Hasegawa, Kensuke Ohta, Takahisa Yamane, Masayuki Hino
Journal: Blood (2004)
Stem Cells Defects in Systemic Sclerosis.
Authors: Nadia Quirici, Nicoletta Del Papa, Cinzia Scavullo, Michela Cortiana, Chiara Borsotti, Wanda Maglione, Denise Comina, Agostino Cortelezzi, Giorgio Lambertenghi Deliliers, Davide Soligo
Journal: Blood (2005)
Apolipoprotein AIV (ApoA-IV) Is a Novel Ligand of Platelet β3 Integrin That Negatively Regulates Platelet Adhesion, Aggregation, and Thrombosis.
Authors: Christopher M. Spring, Wuxun Jin, Hong Yang, Adili Reheman, Guangheng Zhu, Yimin She, Terry Cyr, Patrick Tso, Sean Davidson, John Freedman, Heyu Ni
Journal: Blood (2009)
Many vaccines have tiny amounts of inorganic matter, investigation finds
Authors: Jacqui Wise
Journal: BMJ (2017)

A wide sample of vaccines contained microscopic amounts of non-biodegradable inorganic matter such as lead, stainless steel, and iron, researchers have found. The quality control investigation, published in the International Journal of Vaccines and Vaccination ,1 examined 44 vaccines produced by several manufacturers in France and Italy.

The authors, from the National Council of Research of Italy, said that the …
Loss of red cell ABH Antigens and Hypermethylation of the ABO Gene Promoter region is frequent in Myeloid Malignancies.
Authors: Aline Amorim Martinez, Alessandra Midori Kuniyoshi, Mihoko Yamamoto, Maria de Lourdes Chauffaille, André Luiz Vettore, Akemi Kuroda Chiba, Eliza Yuriko Sugano Kimura, Aline Akemi Nagado, José Orlando Bordin
Journal: Blood (2009)
Attention and memory-driven effects in action studies
Authors: Philip Tseng, Timothy Lane, Bruce Bridgeman
Journal: Behavioral and Brain Sciences (2016)

We provide empirical examples to conceptually clarify some items on Firestone & Scholl's (F&S's) checklist, and to explain perceptual effects from an attentional and memory perspective. We also note that action and embodied cognition studies seem to be most susceptible to misattributing attentional and memory effects as perceptual, and identify four characteristics unique to action studies and possibly responsible for misattributions.
A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) .
Authors: Andres JM Ferreri, Silvia Govi, Giuseppina Patrizia Dognini, Maria Bouzani, Claudia Ruth Bollinguer, Michel D’Incan, Emmanuel Delaporte, Mehdi Hamadani, Fabrice Jardin, Magdalena Martusewicz-Boros, Mauro Montanari, Arpad Szomor, Roberto Crocchiolo, Emanuele Zucca, Franco Cavalli, Maurilio Ponzoni
Journal: Blood (2008)
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
Authors: R T Swords, J Watts, H P Erba, J K Altman, M Maris, F Anwer, Z Hua, H Stein, H Faessel, F Sedarati, B J Dezube, F J Giles, B C Medeiros, D J DeAngelo
Journal: Blood Cancer Journal (2017)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
Patterns of care for 952 patients with newly diagnosed glioblastoma
Authors: L. Bauchet, V. Rigau, H. Mathieu-Daude, P. Fabbro-Peray, M. Fabbro, O. L. Chinot, L. Taillandier, D. Figarella-Branger, F. Labrousse, H. Duffau, J. Honnorat
Journal: Journal of Clinical Oncology (2008)

2052 Background: This work aims to describe oncological patterns of care, prognostic factors and survival for patients (pts) with histologically confirmed glioblastoma (GB) newly diagnosed in France in 2004. Methods: The French Brain Tumor Data Bank identified newly diagnosed and histologically confirmed GB pts in 2004, and collected prospectively initial data. A specific data card was compiled to collect retrospectively the management and the follow up care of these pts from 2004/01/01 to 2006/12/01. Results: 952 pts with newly diagnosed and histologically confirmed GB [males/females 1.6, median age 63.9 yrs, median preoperative Karnofsky performance status (KPS) 80] have been recorded from academic and private institutions in France. Surgery consisted of resection (RS): 541 pts and biopsy (B): 411 pts, with 183 pts with no subsequent oncological treatment. After surgery, first line treatment (n=769) consisted of radiotherapy (RT) and temozolomide (TMZ) concomitant ± adjuvant (RT-TMZ) in 331 pts, RT alone in 236 pts, chemotherapy (CT) alone in 157 pts, and other modality of treatment in 45 pts. The median overall survival of the cohort was 286 days [95% confidence intervals (95%CI) 266- 314] significantly impacted by age, KPS and tumor location (unilateral versus bilateral). Median survival (days, [95%CI]) associated to these main strategies, when analyzed by surgical group, was as followed: RS+RT-TMZ (n=237): 474 [427–506], B+RT-TMZ (n=94): 329 [301–371], RS+RT (n=147): 363 [331–431], B+RT (n=89): 178 [153–237], RS+CT (n=61): 245 [190–361], B+CT (n=96): 244 [198–280], and B only (n=118): 55 [46–71]. Conclusions: This population study confirms in everyday practice results of the pivotal study that define RT and TMZ combination as the new standard of care for GB, and emphasis the role of surgery in this tumor type. No significant financial relationships to disclose.
A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition
Authors: Eytan M. Stein, Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Mojca Jongen-Lavrencic, Jessica K. Altman, Hartmut Dohner, Blythe Thomson, Stephen J. Blakemore, Scott Daigle, Greg Fine, Nigel J. Waters, Andrei V Krivstov, Richard Koche, Scott A. Armstrong, Peter T Ho, Bob Lowenberg, Martin S Tallman
Journal: Blood (2015)
INFLUENZA ACTIVITY - UNITED-STATES AND WORLDWIDE - COMPOSITION OF THE 1992-1993 INFLUENZA VACCINE (REPRINTED FROM MMWR, VOL 41, PG 315-323, 1992)
Authors: K Nerome, M Chakraverty, J Skehel, G Schild, J Wood, [No Value] Gust, J Groothuis, P Graves, G Meiklejohn, A Biache
Journal: JAMA (1992)
T<scp>ranslational</scp>A<scp>dvances</scp><scp>in</scp><scp>the</scp>F<scp>ield</scp><scp>of</scp>P<scp>ulmonary</scp>H<scp>ypertension</scp>.Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension
Authors: Bradley A. Maron, Steven H. Abman
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Reply to M. Løberg et al
Authors: Simer Jit Bains, Milada Mahic, Tor Åge Myklebust, Milada Cvancarova Småstuen, Sheraz Yaqub, Liv Marit Dørum, Bjørn Atle Bjørnbeth, Bjørn Møller, Kristoffer Watten Brudvik, Kjetil Taskén
Journal: Journal of Clinical Oncology (2017)

Løberg et al. comment on our paper [1], where we reported on the association of aspirin use with lower risk of mortality in 23,162 Norwegian patients with colorectal cancer (CRC), of which 6,102 were regular aspirin users post-diagnosis (>6 months use).With a median observation time of 3 years after diagnosis, the hazard ratio (HR) from multivariate Coxregression analyses was 0.85 and 0.95 for CRC-specific survival (CSS) and overall survival (OS), respectively.Løberg et al. [2] focus their criticism on a sub-analysis in our report where we stratified on aspirin use before and after diagnosis of CRC and only after, and cite our finding that in the group that did not use aspirin before CRC diagnosis the HR for aspirin use was 1.0.However, this group was comparably small (1,711 patients that only used aspirin after diagnosis versus 4,391 patents that used aspirin both before and after diagnosis) and with greater uncertainty in the corresponding effect estimate (HR 1.00 (95% CI 0.87-1.14)versus HR 0.77 (CI 0.71-
Hormonal Contraception and Its Association With Depression
Authors: Edward Chesney
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal